

DAFTAR PUSTAKA

1. Well D. 2013. Acne vulgaris: a review of causes and treatment options. *The Nurse Practitioner*. 38(10): 22-31. DOI: 10.1097/01.NPR.0000434089.88606.70.
2. Tan AU, Schlosser BJ, Paller AS. 2018. A review of diagnosis and treatment of acne in adult female patients. *Int J Womens Dermatol*. 4(2): 56–71. DOI: [10.1016/j.ijwd.2017.10.006](https://doi.org/10.1016/j.ijwd.2017.10.006).
3. Bathe K, William HC. 2013. Epidemiology of acne vulgaris. *Br J Dermatol*. 168(3):474–85.
4. Saitta P, Keehan P, Yousif J, Way BV, Grekin S, Brancaccio R. 2011. An update in the presence of psychiatric comorbidities in acne patients. Part 1: overview of prevalence. *Cutis*. 88(1):33–40.
5. Dréno B. What is new in the pathophysiology of acne, an overview. 2017. *J Eur Acad Dermatol Venereol*. 31(S5): 8-12. DOI: [10.1111/jdv.14374](https://doi.org/10.1111/jdv.14374).
6. Mohiuddin AK. 2019. A comprehensive review of acne vulgaris. *Clin Res Dermatol*. 6(2): 1 – 34. DOI: 10.15226/2378-1726/6/2/00186.
7. Thiboutot D, Rosso JQD. 2013. Acne vulgaris and the epidermal barrier: Is Acne Vulgaris Associated with Inherent Epidermal Abnormalities that Cause Impairment of Barrier Functions? Do Any Topical Acne Therapies Alter the Structural and/or Functional Integrity of the Epidermal Barrier? *J Clin Aesthet Dermatol*. 6(2): 18-24.
8. Roudsari MR, Karimi R, Sohrabvandi S, Mortazavian AM. 2015. Health effects of probiotics on the skin. *Crit Rev Food Propr*. 55(9):1219–40. DOI 10.1080/10408398.
9. Gueniche A, Benyacoub J, Phillippe D, Bastien P, Kusy N, Breton L. 2010. *Lactobacillus paracasei* CNCM 1-2116 (ST11) inhibits

substance P-induced skin inflammation and accelerates skin barrier function recovery in vitro. *Eur J Dermatol.* 20:731–7.

10. Heng AHS, Chew FT. 2020. Systematic review of the epidemiology of acne vulgaris. *Sci Rep.* 10(5754). DOI: 10.1038/s41598-020-62715-3.
11. Shen Y, Wang T, Zhou C *et al.* 2012. Prevalence of acne vulgaris in Chinese adolescents and adults: a community-based study of 17,345 subjects in six cities. *Acta Derm Venereol.* 92(1):40–4. DOI: 10.2340/00015555-1164.
12. Tan JKL, Bhate K. 2015. A global perspective on the epidemiology of acne. *Br J Dermatol.* 172(S1): 3-12. DOI: [10.1111/bjd.13462](https://doi.org/10.1111/bjd.13462).
13. Lynn DD, Umari T, Dunnick CA, Dellavalle RP. 2016. The epidemiology of acne vulgaris in late adolescence. *Adolesc Health Med Ther.* 7: 13-25. DOI: 10.2147/AHMT.S55832.
14. Melnik BC. Melnik, B. C. 2010. FoxO1 - the key for the pathogenesis and therapy of acne? *JDDG: Journal Der Deutschen Dermatologischen Gesellschaft.* 8(2): 105–14. doi:10.1111/j.1610-0387.2010.07344.x.
15. Lehmann HP, Robinson KA, Andrews JS, Holloway V, Goodman SN. 2002. Acne therapy: a methodologic review. *J Am Acad Dermatol.* 47(2): 231–240. DOI:10.1067/mjd.2002.120912.
16. Kraft J, Freiman A. 2011. Management of acne. *CMAJ.* 183: E430-5. DOI: 10.1503/cmaj.090374.
17. Baz K, Erdal M, Yazici A, Soymelez F, Guvenc U, Tasdelen B, Ikizoglu G. 2008. Association between tumor necrosis factor-alpha gene promoter polymorphism at -308 and acne in Turkish patients. *Arch Dermatol Res.* 300: 371–6.
18. Goodarzi A, Mozafarpour S, Bodaghabadi M, Mohamadi M. 2020. The potential of probiotics for treating acne vulgaris: a review of literature on acne and microbiota. *Dermatol Ther.* 33(3):e13279. doi: 10.1111/dth.13279).


19. Sullivan M, Schnittger SF, Mammone T, Goyarts EC. 2009. Skin treatment method with Lactobacillus extract. US Patent 7,510,734 B2.
20. Adebamowo CA, Spiegelman D, Berkey CS, et al. 2006. Milk consumption and acne in adolescent girls. *Dermatol Online J.*12:1.
21. Adebamowo CA, Spiegelman D, Berkey CS, Danby FW, et al. 2008. Milk consumption and acne in teenaged boys. *J Am Acad Dermatol.* 58:787–93.
22. Adebamowo CA, Spiegelman D, Danby FW, et al. 2005. High school dietary dairy intake and teenage acne. *J Am Acad Dermatol.* 52:207–14.
23. Anon. 2006. FAO/WHO. Guidelines for the Evaluation of Probiotics in Food. Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food.
24. Bowe, W. P., Filip, J. C., Dirienzo, J. M., et al. 2006. Inhibition of propionibacterium acnes by bacteriocin-like inhibitory substances (BLIS) produced by *Streptococcus salivarius*. *J Drugs Dermatol.* 5: 868–70.
25. Caramia G, Atzei A, Fanos V. 2008. Probiotics and the skin. *Clinics in Dermatology.* 26:4–11.
26. Cinque B, Palumbo P, La Torre C, et al. 2010. Probiotics in aging skin. *Textbook of aging skin.* Berlin: Springer.
27. Cinque B, Torre C, Melchiorre E, et al. 2011. Use of Probiotics for Dermal Applications. In: LIONG, M.-T. (ed.) *Probiotics, Microbiology Monographs.* Verlag Berlin Heidelberg: Springer.
28. Di Marzio L, Centi C, Cinque B, et al. 2003. Effect of the lactic acid bacterium *Streptococcus thermophilus* on stratum corneum ceramide levels and signs and symptoms of atopic dermatitis patients. *Exp. Dermatol.* 12:615–20.
29. Di Marzio L, Cinque B, Cupelli, et al. 2008. Increase of skin-ceramide levels in aged subjects following a short-term topical application of

- bacterial sphingomyelinase from *Streptococcus thermophilus*. *Int. J. Immunopathol. Pharmacol.* 21:137–43.
30. Di Marzio L, Cinque B, De Simone C, Cifone MG. 1999. Effect of the lactic acid bacterium *Streptococcus thermophilus* on ceramide levels in human keratinocytes in vitro and stratum corneum in vivo. *J. Invest Dermatol.* 113:98–106.
 31. Euvrard S, Kanitakis J, Claudy A. 2003. Skin cancers after organ transplantation. *N. Engl. J. Med.* 348:1681–91.
 32. Grice EA, Kong HH, Renaud G, et al. 2008. A diversity profile of the human skin microbiota. *Genome Res.* 18:1043–50.
 33. Kang BS, Seo JG, Lee GS, et al. 2009. Antimicrobial activity of enterocins from *Enterococcus faecalis* SL-5 against *Propionibacterium acnes*, the causative agent in acne vulgaris, and its therapeutic effect. *J. Microbiol.* 47:101–9.
 34. Kang SH, Kim JU, Imm JY, Oh S, Kim SH. 2006. The effects of dairy processes and storage on insulin-like growth factor-I (IGF-I) content in milk and in model IGF-I-fortified dairy products. *J. Dairy Sci.* 89: 402–9.
 35. Kim J, Ko Y, Park YK, Kim NI, Ha WK, Cho Y. 2010. Dietary effect of lactoferrin-enriched fermented milk on skin surface lipid and clinical improvement of acne vulgaris. *Nutrition and Cancer.* 26:902–9.
 36. Krutmann J. 2009. Pre- and probiotics for human skin. *Journal of Dermatological Science.* 54:1–5.
 37. Lee WJ, Jung HD, Lee HJ, Kim BS, Lee SJ, Kim DW. 2008b. Influence of substance-P on cultured sebocytes. *Arch. Dermatol. Res.* 300:311–6.
 38. Melnik BC, Schmitz G. 2009. Role of insulin, insulin-like growth factor-1, hyperglycaemic food and milk consumption in the pathogenesis of acne vulgaris. *Exp. Dermatol.* 18:833–41.
 39. Ouwehand AC, Salminen S, Isolauri E. 2002. Probiotics: an overview of beneficial effects. *Antonie van Leeuwenhoek.* 82:279–89.

40. Pavicic T, Wollenweber U, Farwick M, Korting HC. 2007. Anti-microbial and -inflammatory activity and efficacy of phytosphingosine: an in vitro and in vivo study addressing acne vulgaris. *Int. J. Cosmet Sci.* 29:181–90.
41. Quadros E, Landzert NM, Leroy S, Gasparini F, Worosila G. 1994. Colonic absorption of insulin-like growth factor I in vitro. *Pharm. Res.* 11:226–30.
42. Salminen SJ, Gueimonde M, Isolauri E. 2005. Probiotics that modify disease risk. *J Nutr.* 135:1294–8.
43. Schmidt WP. 2004. Model of the epidemic of childhood atopy. *Med Sci Monit.* 10:5–9.
44. Volkova LA, Khalif IL, Kabanova IN. 2001. Impact of the impaired intestinal microflora on the course of acne vulgaris. *Klin Med.* 79:39–41.
45. Woods GM, Malley RC, Muller HK. 2005. The skin immune system and the challenge of tumour immunosurveillance. *Eur J Dermatol.* 15: 63.
46. Sibero HT, Sirajudin A, dkk. Prevalensi dan Gambaran Epidemiologi Akne Vulgaris di Provinsi Lampung The Prevalence and Epidemiology of Acne Vulgaris in Lampung. *J Farm Komunitas.* 2019;3(2):62–8.
47. Teresa A. Akne Vulgaris Dewasa : Etiologi, Patogenesis Dan Tatalaksana Terkini. *J Kedokt.* 2020;8(1):952–64.
48. Reti Anggraeni, Fiska Rosita, Arie Kusumawardani. 2021. Terapi Probiotik (*Lactococcus lactis*) Topikal untuk Akne Vulgaris: Kasus Serial. *CDK-292/ vol. 48 no. 1.*
49. Dreno B, Martin R, Moyal D, Henley J, Khammari A, Seité S. Skin microbiome and acne vulgaris: *Staphylococcus*, a new actor in acne. *Exp Dermatol.* 2017;26(9):798–803.

50. Goodarzi A, Mozafarpour S, Bodaghabadi M, Mohamadi M. The potential of probiotics for treating acne vulgaris: A review of literature on acne and microbiota. *Dermatol Ther*. 2020;33(3).
51. N M, W M, M S, S S, T M. Physiological effect of a probiotic on skin. *J Cosmet Sci* [Internet]. 2012 Nov 1 [cited 2021 Aug 22];63(6):385–95. Available from: <https://pubmed.ncbi.nlm.nih.gov/23286870/>
52. Mottin VHM, Suyenaga ES. An approach on the potential use of probiotics in the treatment of skin conditions: acne and atopic dermatitis. *Int J Dermatol*. 2018;57(12):1425–32
53. Kober M-M, Bowe WP. The effect of probiotics on immune regulation, acne, and photoaging. *Int J Women's Dermatology* [Internet]. 2015 [cited 2021 Aug 20];1(2):85. Available from: [/pmc/articles/PMC5418745](https://pubmed.ncbi.nlm.nih.gov/27111111/)

LAMPIRAN




KIT ELISA TNF ALFA

PENGAMBILAN SAMPEL



PEMERIKSAAN SPESIMEN DI LABORATORIUM



PREPARAT TOPIKAL DAN SABUN PEMBERSIH WAJAH
DARI PT. DION FARMA ABADI



BERISI PLACEBO



BERISI *LACTOCOCCUS FERMENT LYSATE*



SABUN PEMBERSIH WAJAH



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN



RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 47/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 31 Januari 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22010004	No Sponsor	
Peneliti Utama	Prof. Dr. dr. Anis Irawan Anwar, Sp.KK(K), FINSDV, FAADV	Sponsor	
Judul Peneliti	EFEKTIVITAS MIKROBIOM TOPIKAL YANG MENGANDUNG LACTOBACILLUS PLANTARUM TERHADAP KADAR IL 8, IL 12, TNF ALPHA DAN ANTI INFLAMASI IL 10 SEBAGAI PENGOBATAN ACNE VULGARIS		
No Versi Protokol	2	Tanggal Versi	28 Januari 2022
No Versi PSP	2	Tanggal Versi	28 Januari 2022
Tempat Penelitian	RS Universitas Hasanuddin dan RS Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input checked="" type="checkbox"/> Fullboard Tanggal 18 Januari 2022	Masa Berlaku	Frekuensi review lanjutan
Ketua KEPK FKUH RSUH dan RSWS	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris KEPK FKUH RSUH dan RSWS	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

**SURAT PERNYATAAN PERSETUJUAN
UNTUK IKUT SERTA DALAM PENELITIAN
(INFORMED CONSENT)**

Yang bertanda tangan dibawah ini:

Nama :
Usia :
Alamat :
Pekerjaan :
No. KTP/lainnya:

Dengan ini menyatakan bahwa:

Telah memperoleh penjelasan sepenuhnya, menyadari, mengerti, dan memahami tentang tujuan, manfaat dan risiko yang mungkin timbul dalam penelitian yang berjudul:

**"Efektivitas Mikrobiom Topikal yang Mengandung Lactococcus Ferment
Lysate Terhadap IL 12, IL 8, TNF Alpha, IL 10, dan IL 1 sebagai
Pengobatan Akne Vulgaris**

"

Maka dengan ini saya menyatakan :

setuju/tidak setuju*) berperan serta dalam penelitian ini

Demikian surat pernyataan ini kami buat dengan sesungguhnya dan tanpa paksaan.

Makassar, 2022

Peserta penelitian,

(.....)